PF-06821497 再発/難治性 SCLC、去勢抵抗性前立腺がん、濾胞性リンパ腫の治療
再発/難治性小細胞肺がん (SCLC)、去勢抵抗性前立腺がん (CRPC)、および濾胞性リンパ腫 (FL) の成人患者の治療における PF-06821497 の第 I 相用量漸増および拡大コホート研究
The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) and Follicular Lymphoma (FL). The study consists of 3 parts; Part 1 and 2 enrolled participants with SCLC, metastatic CRPC, and FL are closed for enrollment.
Part 3, which is open for enrollment is seeking men who:
- have Castration Resistant Prostate Cancer (CRPC) and
- have previously received treatment for CRPC and have progressed from the last treatment
All participants in Part 3 of this study will receive mevrometostat and/ or enzalutamide. Part 3 consists of 2 sub studies each has an assessment phase and a maintenance phase. The Part 3 DDI substudy consist of 2 cohorts, Cohort 1 (monotherapy cohort) and Cohort 2 (Combination cohort).
In the assessment phase:
- participants in the BE substudy will take 3 single doses of mevrometostat by mouth over 3 periods.
- participants in the DDI substudy Cohort 1 (monotherapy cohort) will take mevrometostat 2 times a day and/or itraconazole 1 time a day based on a present schedule.
- participants in the DDI substudy Cohort 2 (combination cohort) will take mevrometostat 2 times a day, enzalutamide 1 time a day, and/or itraconazole 1 time a day based on a present schedule.
After completion of the assessment phase, participants will enter the maintenance phase where they will receive mevrometostat 2 times a day and enzalutamide 1 time a day by mouth until their cancer is no longer responding.
The study will look at the experiences of participanrs receiving the study medicine. This will help see if the study medicine is safe and effective.
調査の概要
状態
詳細な説明
This is an open label, multi center, Phase 1 dose escalation and dose expansion study of mevrometostat (PF-06821497) administered orally BID as a single agent or in combination with SOC to patients with CRPC, SCLC, and FL. The study consists of three parts (Part 1, Part 2, and Part 3) along with the Japan and China monotherapy cohorts. Part 1 and Part 2 are closed for enrollment. Part 1 tested monotherapy in 3 cohorts (Parts 1A, 1B, and 1C); Part 2 tested combination therapy in Parts 2A (dose escalation), 2B and 2C (does expansion).
Part 3 consists of the Bioequivalence (BE) and drug-drug interaction (DDI) substudies and are open for enrollment. The BE substudy will test between 2 mevrometostat formulation to confirm that they work in the body the same way. The DDI substudy will evaluate the effect of a strong CYP3A4 (an enzyme in your body that breaks down/ removes drugs) inhibitor on the PK of mevrometostat; a strong CYP3A4 inhibitor may slow down the breakdown/ removal of drugs in your body. The Sponsor may choose to delay or discontinue any cohorts or substudies.
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Pfizer CT.gov Call Center
- 電話番号:1-800-718-1021
- メール:ClinicalTrials.gov_Inquiries@pfizer.com
研究場所
-
-
Arizona
-
Tucson、Arizona、アメリカ、85719
- 積極的、募集していない
- Banner-University Medical Center Tucson
-
Tucson、Arizona、アメリカ、85719
- 積極的、募集していない
- The University of Arizona Cancer Center-North Campus
-
Tucson、Arizona、アメリカ、85724
- 積極的、募集していない
- The University of Arizona Cancer Center
-
Tucson、Arizona、アメリカ、85741
- 終了しました
- Arizona Urology Specialists, PLLC
-
-
California
-
Anaheim、California、アメリカ、92801
- 積極的、募集していない
- Pacific Cancer Medical Center INC
-
Duarte、California、アメリカ、91010
- 積極的、募集していない
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
-
Duarte、California、アメリカ、91010
- 積極的、募集していない
- City of Hope Investigational Drug Services (IDS)
-
-
Connecticut
-
Norwalk、Connecticut、アメリカ、06856
- 積極的、募集していない
- Norwalk Hospital
-
-
Kansas
-
Fairway、Kansas、アメリカ、66205
- 積極的、募集していない
- The University of Kansas Cancer Center, Investigational Drug Services
-
Fairway、Kansas、アメリカ、66205
- 積極的、募集していない
- The University of Kansas Clinical Research Center
-
Kansas City、Kansas、アメリカ、66160
- 積極的、募集していない
- The University of Kansas Hospital
-
Kansas City、Kansas、アメリカ、66160
- 積極的、募集していない
- The University of Kansas Medical Center Medical Office Building
-
Overland Park、Kansas、アメリカ、66211
- 積極的、募集していない
- The University of Kansas Cancer Center - Indian Creek Campus
-
Westwood、Kansas、アメリカ、66205
- 積極的、募集していない
- The University of Kansas Cancer Center
-
-
Kentucky
-
Louisville、Kentucky、アメリカ、40202
- 積極的、募集していない
- Norton Cancer Institute, Norton Healthcare Pavilion
-
Louisville、Kentucky、アメリカ、40202
- 積極的、募集していない
- Norton Hospital
-
Louisville、Kentucky、アメリカ、40202
- 積極的、募集していない
- Norton Cancer Institute - Downtown
-
-
Maryland
-
Rockville、Maryland、アメリカ、20850
- 終了しました
- Maryland Oncology Hematology, P.A.
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02215
- 積極的、募集していない
- Dana-Farber Cancer Institute
-
Boston、Massachusetts、アメリカ、02115
- 積極的、募集していない
- Brigham and Women's Hospital
-
Newton、Massachusetts、アメリカ、02459
- 積極的、募集していない
- Dana Farber Cancer Institute- Chestnut Hill
-
-
Nebraska
-
Omaha、Nebraska、アメリカ、68130
- 募集
- Oncology Hematology West, PC dba Nebraska Cancer Specialists
-
-
New Jersey
-
Hackensack、New Jersey、アメリカ、07601
- 積極的、募集していない
- Hackensack University Medical Center
-
Hackensack、New Jersey、アメリカ、07601
- 積極的、募集していない
- John Theurer Cancer Center at Hackensack University Medical Center
-
-
Oklahoma
-
Oklahoma City、Oklahoma、アメリカ、73104
- 募集
- OU Health University of Oklahoma Medical Center
-
Oklahoma City、Oklahoma、アメリカ、73104
- 募集
- Stephenson Cancer Center (chemo location)
-
-
South Carolina
-
Myrtle Beach、South Carolina、アメリカ、29572
- 募集
- Carolina Urologic Research Center
-
Myrtle Beach、South Carolina、アメリカ、29572
- 募集
- Parkway Surgery Center
-
-
Tennessee
-
Nashville、Tennessee、アメリカ、37203
- 募集
- Sarah Cannon Research Institute - Pharmacy
-
Nashville、Tennessee、アメリカ、37203
- 募集
- SCRI Oncology Partners
-
-
Texas
-
Austin、Texas、アメリカ、78705
- 終了しました
- Texas Oncology - Austin Midtown
-
Dallas、Texas、アメリカ、75390
- 積極的、募集していない
- UT Southwestern Medical Center
-
Dallas、Texas、アメリカ、75390
- 積極的、募集していない
- University of Texas Southwestern Medical Center - Simmons Cancer Center
-
Dallas、Texas、アメリカ、75390
- 積極的、募集していない
- UT Southwestern University Hospital - William P. Clements, Jr
-
Dallas、Texas、アメリカ、75390
- 積極的、募集していない
- UT Southwestern University Hospital - Zale Lipshy
-
Irving、Texas、アメリカ、75063
- 終了しました
- US Oncology Investigational Product Center (IPC)
-
Irving、Texas、アメリカ、75063
- 終了しました
- US Oncology Investigational Products Center
-
Irving、Texas、アメリカ、75039
- 募集
- NEXT Dallas
-
San Antonio、Texas、アメリカ、78229
- 募集
- NEXT Oncology
-
San Antonio、Texas、アメリカ、78240
- 積極的、募集していない
- NEXT Oncology
-
-
Virginia
-
Fairfax、Virginia、アメリカ、22031
- 積極的、募集していない
- Virginia Cancer Specialists, PC
-
-
Washington
-
Port Angeles、Washington、アメリカ、98362
- 積極的、募集していない
- Olympic Medical Center
-
Poulsbo、Washington、アメリカ、98370
- 積極的、募集していない
- Fred Hutchinson Cancer Center Alliance Peninsula
-
Seattle、Washington、アメリカ、98109
- 積極的、募集していない
- Fred Hutchinson Cancer Center
-
Seattle、Washington、アメリカ、98109
- 積極的、募集していない
- University of Washington Medical Center
-
-
-
-
-
Barcelona、スペイン、08035
- 募集
- Hospital Universitari Vall d'Hebron
-
Barcelona、スペイン、08036
- 募集
- Hospital Clinic de Barcelona
-
Barcelona、スペイン、08023
- 募集
- Hospital Quironsalud Barcelona
-
Madrid、スペイン、28034
- 募集
- Hospital Universitario Ramon y Cajal
-
Madrid、スペイン、28040
- 募集
- Hospital Clinico San Carlos
-
Madrid、スペイン、28050
- 募集
- Hospital Universitario HM Sanchinarro
-
Madrid、スペイン、28040
- 募集
- H.U. Fundación Jiménez Díaz
-
Madrid、スペイン、28041
- 募集
- Hospital Universitario 12 De Octubre
-
Málaga、スペイン、29010
- 募集
- Hospital Universitario Virgen de la Victoria
-
Valencia、スペイン、46026
- 積極的、募集していない
- Hospital Universitari i Politecnic La Fe
-
-
Barecelona
-
L'Hospitalet de Llobregat、Barecelona、スペイン、08908
- 積極的、募集していない
- Institut Català d´Oncología (ICO)-H. Durán i Reynals
-
-
Castellon
-
Castellon、Castellon、スペイン、12002
- 積極的、募集していない
- Consorcio Hospitalario Provincial de Castellon
-
-
Madrid
-
Pozuelo de Alarcón、Madrid、スペイン、28223
- 募集
- Hospital Quironsalud Madrid
-
-
-
-
-
Haskovo、ブルガリア、6300
- 終了しました
- Specialized Hospital for Active Treatment of Oncology - Haskovo
-
-
-
-
-
Bydgoszcz、ポーランド、85-048
- まだ募集していません
- In-Vivo Sp. z o.o. In-vivo Bydgoszcz
-
Koszalin、ポーランド、75-581
- 積極的、募集していない
- Szpital Wojewódzki im. Mikołaja Kopernika w Koszalinie
-
Krakow、ポーランド、30-348
- 募集
- Centrum Badań Klinicznych Jagiellońskie Centrum Innowacji sp. z o.o.
-
Rzeszów、ポーランド、35-326
- 積極的、募集していない
- Centrum Medyczne MEDYK
-
Warsaw、ポーランド、02-781
- 積極的、募集していない
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie
-
-
-
-
-
Moscow、ロシア、117186
- 積極的、募集していない
- LLC "Neyro-klinika"
-
Moscow、ロシア、125284
- 終了しました
- Moscow GBUZ "City clinical hospital n. a. S.P. Botkina" of Moscow health department
-
Moscow、ロシア、129301
- 終了しました
- SBHI of Moscow City Clinical Hospital
-
Omsk、ロシア、644013
- 終了しました
- Budgetary Healthcare Institution of Omsk region "Clinical Oncological Dispensary"
-
Saint Petersburg、ロシア、197341
- 終了しました
- Federal State Budgetary Institution National Medical Research Center n.a. V.A. Almazov
-
Saint Petersburg、ロシア、197758
- 終了しました
- Federal State Budgetary Institution National Medical Research Center for Oncology n.a. N.N.
-
Saint Petersburg、ロシア、198255
- 終了しました
- Saint Petersburg State Budgetary Healthcare Institution "City Clinical Oncological Dispensary"
-
Yaroslavl、ロシア、150054
- 終了しました
- State Budgetary Healthcare Institution of the Yaroslavl Region
-
-
Sankt-Peterburg
-
Pushkin、Sankt-Peterburg、ロシア、196603
- 積極的、募集していない
- Private Medical Institution "Euromedservice"
-
-
-
-
Guangdong
-
Guangzhou、Guangdong、中国、510120
- 積極的、募集していない
- The First Affiliated Hospital of Guangzhou Medical University
-
-
Hunan
-
Changsha、Hunan、中国、410013
- 積極的、募集していない
- Hunan Cancer Hospital
-
-
Jiangsu
-
Nanjing、Jiangsu、中国、210009
- 積極的、募集していない
- Zhongda Hospital Southeast University
-
Nanjing、Jiangsu、中国、210008
- 積極的、募集していない
- Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School
-
-
Sichuan
-
Chengdu、Sichuan、中国、610041
- 募集
- West China Hospital, Sichuan University
-
-
Zhejiang
-
Wenzhou、Zhejiang、中国、325000
- 積極的、募集していない
- The First Affiliated Hospital of Wenzhou Medical University
-
-
-
-
Chiba
-
Kashiwa、Chiba、日本、277-8577
- 積極的、募集していない
- National Cancer Center Hospital East
-
-
-
-
Kyǒnggi-do
-
Seongnam、Kyǒnggi-do、韓国、13620
- 募集
- Seoul National University Bundang Hospital
-
-
Seoul-teukbyeolsi [seoul]
-
Seoul、Seoul-teukbyeolsi [seoul]、韓国、03080
- 積極的、募集していない
- Seoul National University Hospital
-
Seoul、Seoul-teukbyeolsi [seoul]、韓国、07985
- 積極的、募集していない
- Ewha Womans University Mokdong Hospital
-
Seoul、Seoul-teukbyeolsi [seoul]、韓国、03722
- 積極的、募集していない
- Severance Hospital, Yonsei University Health System
-
-
Taejǒn-kwangyǒkshi
-
Daejeon、Taejǒn-kwangyǒkshi、韓国、35015
- 積極的、募集していない
- Chungnam national university hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Part 1 and Part 2 (Closed for enrollment).
Part 3 Key Inclusion Criteria:
- Histological or cytological diagnosis of castration resistant prostate cancer.
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0-2 with expected life expectancy of at least 6 months.
- Adequate bone marrow, renal, and liver function
Part 3 Key Exclusion Criteria:
- Prior irradiation to >25% of the bone marrow.
- QTcF interval >480 msec at screening.
- Hypertension that cannot be controlled by medications (>150/90 mmHg despite optimal medical therapy).
- Known or suspected hypersensitivity to PF 06821497 or any components or enzalutamide (CRPC)
- Active inflammatory gastrointestinal disease, chronic diarrhea, known diverticular disease or previous gastric resection or lap band surgery.
- Current use or anticipated need for food or drugs that are known strong and moderate CYP3A4/5 inducers or inhibitors
- Prior enzalutamide within the last 4 weeks
- DDI SUBSTUDY:
- history of CHF or evidence of ventricular dysfunction
- fructose intolerance
- coadministration of CYP3A4 substrates
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Dose Escalation (Part 1A)
Participants with SCLC, CRPC and FL will receive mevrometostat at escalating dose levels |
Oral continuous
他の名前:
|
|
実験的:Dose Escalation (Part 1B)
Participants with FL will receive mevrometostat at escalating dose levels |
Oral continuous
他の名前:
|
|
実験的:Dose Escalation (Part 1C)
Participants with mCRPC will receive mevrometostat at escalating dose levels. |
Oral continuous
他の名前:
|
|
実験的:Dose Escalation (Part 2A)
Participants with mCRPC and SCLC will receive mevrometostat at escalating dose levels in combination with SOC. |
Oral continuous
他の名前:
Oral continuous
他の名前:
|
|
実験的:Dose Expansion (Part 2B)
Participants with CRPC will receive mevrometostat in combination with SOC or SOC alone. |
Oral continuous
他の名前:
Oral continuous
他の名前:
|
|
実験的:Japan Cohort
Participants with CRPC will receive mevrometostat at one or two doses |
Oral continuous
他の名前:
|
|
実験的:China cohort
Participants will receive mevrometostat at one or two doses |
Oral continuous
他の名前:
|
|
実験的:Dose Expansion (Part 2C)
Participants with mCRPC will receive mevrometostat at a different dose/dosing regimen than that of Part 2B in combination with SOC |
Oral continuous
他の名前:
Oral continuous
他の名前:
|
|
実験的:BE Substudy
In the assessment phase, each enrolled participant will receive single doses of the 2 different mevrometostat formulations in 3 periods with alternating dosing and washout between each dose. In the maintenance phase, each participant will receive mevrometostat 2 times a day and enzalutamide 1 time a day. |
Oral continuous
他の名前:
Oral continuous
他の名前:
|
|
実験的:DDI Substudy
The DDI substudy assessment phase will consist of 2 Cohorts, Cohort 1 (monotherapy cohort) and Cohort 2 (combination cohort). In the Cohort 1 assessment phase, each enrolled participant will receive a combination of mevrometostat and itraconazole based on preset schedule. In the Cohort 2 assessment phase, each enrolled participant will receive a combination of mevrometostat, enzalutamide, and itraconazole based on preset schedule. In the maintenance phase, each participant will receive mevrometostat 2 times a day and enzalutamide 1 time a day. |
Oral continuous
他の名前:
Oral continuous
他の名前:
Oral solution
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of patients with dose limiting toxicities (DLTs) to determine the maximum tolerated dose (MTD)
時間枠:Baseline up to 90 days
|
First cycle DLTs will be utilized to determine the MTD |
Baseline up to 90 days
|
|
Overall safety profile including adverse events
時間枠:Baseline up to approximately 2 years
|
Adverse Events will be graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version [4.03]) |
Baseline up to approximately 2 years
|
|
Preliminary efficacy determination as evaluated by disease specific response criteria
時間枠:Through study completion, approximately 2 years past last patient first visit.
|
Objective response using Response Evaluation Criteria in Lymphoma (RECIL) for lymphoma, Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for solid tumors including Small Cell Lung Cancer (SCLC) and Prostate Cancer Working Group 3 (PCWG3) for Castration Resistant Prostate Cancer (CRPC). Progression-free survival in Part 2B in patients with CRPC. |
Through study completion, approximately 2 years past last patient first visit.
|
|
Overall safety profile including laboratory abnormalities
時間枠:Baseline up to approximately 2 years
|
Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version [4.03]), and timing. |
Baseline up to approximately 2 years
|
|
Overall safety profile including vital signs
時間枠:Baseline up to approximately 2 years
|
Vital sign changes from baseline including blood pressure, heart rate, ECG changes. |
Baseline up to approximately 2 years
|
|
Evaluate time to event mevrometostat and enzalutamide vs enzalutamide alone including radiographic prgression free survival
時間枠:Baseline until disease progression or death or through study completion (approx 2 years)
|
PCWG3 |
Baseline until disease progression or death or through study completion (approx 2 years)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Evaluate time to event anti-tumor activity of mevrometostat including progression-free survival (PFS), PSA50, Duration of Response (DoR), Time to first skeletal related event and Time to symptomatic skeletal related event, depending on tumor type.
時間枠:Baseline and every 21 days through time of confirmed disease progression, unacceptable toxicity, or through study completion, approximately 2 years.
|
Time to event endpoints based on Response Evaluation Criteria in Lymphoma (RECIL) for lymphoma, Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for solid tumors including Small Cell Lung Cancer (SCLC) and Prostate Cancer Working Group 3 (PCWG3) for Castration Resistant Prostate Cancer (CRPC) |
Baseline and every 21 days through time of confirmed disease progression, unacceptable toxicity, or through study completion, approximately 2 years.
|
|
Evaluate overall survival
時間枠:Baseline up to approximately 2 years
|
Median time to death proportion of patients alive at 6 months, 1 year, and 2 years. |
Baseline up to approximately 2 years
|
|
Pharmacokinetic Parameters: Maximum Observed Plasma Concentration (Cmax)
時間枠:At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Single dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Pharmacokinetic Parameters: Time to Reach Maximum Observed Plasma Concentration (Tmax)
時間枠:At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Single dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Pharmacokinetic Parameters: Area Under the Curve (AUC)
時間枠:At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Single dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Pharmacokinetic Parameters: Apparent Oral Clearance (CL/F)
時間枠:At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Single dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Pharmacokinetic Parameters: Apparent Volume of Distribution (Vz/F)
時間枠:At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Single dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Pharmacokinetic Parameters: Plasma Decay Half-Life (t1/2)
時間枠:At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Singe dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Evaluate the impact of mevrometostat on patient reported outcomes.
時間枠:At specific time-points from Cycle 1 Day 1 to End of Treatment visit.
|
Quality of Life and Time to Functional Status Deterioration as assessed by FACT-P. |
At specific time-points from Cycle 1 Day 1 to End of Treatment visit.
|
|
Impact of mevrometostat in combination with enzalutamide, enzalutamide alone and mevrometostat alone on symptoms and symptomatic toxicity
時間枠:At specific time points from Cycle1 Day 1 to end of treatment
|
Questionnaire customized from PRO-CTCAE. |
At specific time points from Cycle1 Day 1 to end of treatment
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Pfizer CT.gov Call Center、Pfizer
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- C2321001
- 2023-509179-18-00 (レジストリ識別子:CTIS (EU))
- EZH2 (その他の識別子:Alias Study Number)
- 2023 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。